Next earnings date: 28 Aug 2025

Can-Fite BioPharma Ltd. – AMEX:CANF

Add to watchlist

$0.65

-0.93

-58.86%

Market closed

Open in about 12 hours

-54.47%

month

-54.47%

quarter

-28.18%

year

Market Cap	9.08M
Enterprise value	4.26M

P/E	-0.57
EV/Sales	4.69
EV/EBITDA	-0.37
Price/Sales	8.71
Price/Book	1.06
PEG ratio	-0.04
EPS	-1.81

Revenue	743K
EBITDA	-8.19M
Income	-7.47M
Revenue Q/Q	-21.31%
Revenue Y/Y	-8.27%

Profit margin	-1247.41%
Oper. margin	-1241.58%
Gross margin	0%
EBIT margin	-1241.58%
EBITDA margin	-1102.96%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Can-Fite BioPharma Ltd. (AMEX:CANF): Profit margin
Mar 2023	196K	-2.38M	-1218.37%
Jun 2023	196K	-1.67M	-852.04%
Sep 2023	196K	-1.76M	-898.98%
Dec 2023	155K	-1.65M	-1065.81%

Can-Fite BioPharma Ltd. Financials Estimate

Q Y

Can-Fite BioPharma Ltd. (AMEX:CANF): Analyst Estimates
2025	900K	-4.72M	-525.54%
2026	800K	-213.05K	-26.63%
2027	43.34M	4.98M	11.5%
2028	310.88K	9.97M	3207.35%

Analysts Price target
Financials & Ratios estimates

Can-Fite BioPharma Ltd. (AMEX:CANF): Earnings per share (EPS)
2024-06-27	-0.4	-0.65
2024-09-26	-0.4	-0.4
2024-12-05	-0.27	-0.27

Can-Fite BioPharma Ltd. (AMEX:CANF): Payout ratio
Payout ratio	0%

Can-Fite BioPharma Ltd. (AMEX:CANF): Dividend Yield
2019
2020
2021	0.01%
2022	0.05%
2023

Can-Fite BioPharma Ltd. (AMEX:CANF): Debt to assets
Mar 2023	13489000	4.99M	37.04%
Jun 2023	11032000	4.15M	37.69%
Sep 2023	9169000	3.93M	42.91%
Dec 2023	9989000	3.74M	37.5%

Can-Fite BioPharma Ltd. (AMEX:CANF): Cash Flow
Mar 2023	0	0	0
Jun 2023	95K	0	0
Sep 2023	0	0	0
Dec 2023	0	0	0

Can-Fite BioPharma Ltd. alternative data

Can-Fite BioPharma Ltd.
Employees

Can-Fite BioPharma Ltd. (AMEX:CANF): Employee count
Aug 2023	8
Sep 2023	8
Oct 2023	8
Nov 2023	8
Dec 2023	8
Jan 2024	8
Feb 2024	8
Mar 2024	8
Apr 2024	8
May 2024	8
Jun 2024	8
Jul 2024	8

Can-Fite BioPharma Ltd.
Hedge Funds Holdings Q1 2023

0.01% -0.05%

of CANF is owned by hedge funds

4 -5

hedge funds hold CANF stock

4.86K -37.84K

shares is hold by hedge funds

CANF hedge funds holdings changes

Can-Fite BioPharma Ltd.
Patents

Status	Patent	Filling date	Issue date
Grant	Grant Utility: Method for treating fibrotic liver tissue using Cl-IB-MECA Filling date: 26 Aug 2020 Issue date: 5 Apr 2022	26 Aug 2020	5 Apr 2022
Application	Application AN A3 ADENOSINE RECEPTOR LIGAND FOR USE FOR ACHIEVING A FAT LOSS EFFECT Filling date: 5 Jan 2020 Issue date: 17 Mar 2022	5 Jan 2020	17 Mar 2022
Application	Application A3 ADENOSINE RECEPTOR LIGAND FOR MANAGING CYTOKINE RELEASE SYNDROME Filling date: 16 Sep 2018 Issue date: 11 Mar 2021	16 Sep 2018	11 Mar 2021
Application	Application A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION Filling date: 26 Aug 2020 Issue date: 10 Dec 2020	26 Aug 2020	10 Dec 2020
Grant	Grant Utility: Method for treating NASH accompanied by fibrosis using Cl-IB-MECA Filling date: 22 May 2018 Issue date: 22 Sep 2020	22 May 2018	22 Sep 2020

CANF patents

Can-Fite BioPharma Ltd.
Earnings Call Transcripts

Quarter	Transcript
Q3 2020 30 Nov 2020	Q3 2020 Earnings Call Transcript
Q2 2020 28 Aug 2020	Q2 2020 Earnings Call Transcript
Q1 2020 1 Jun 2020	Q1 2020 Earnings Call Transcript

CANF earnings call transcripts

Can-Fite BioPharma Ltd.
Executives

Insider	Age	Compensation
Dr. Pnina Fishman Ph.D. (1948) Scientific Founder, Chief Executive Officer & Director	77	$598,000
Mr. Motti Farbstein (1964) Chief Operating & Financial Officer	61	$415,000
Dr. Sari Fishman Ph.D. (1972) Vice President of Bus. Devel.	53	$286,000

Can-Fite BioPharma Ltd.
Latest News

Monday, 30 December 2024
07:00	Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson	globenewswire.com
Monday, 9 December 2024
10:56	Bears are Losing Control Over CanFite Biopharma (CANF), Here's Why It's a 'Buy' Now	zacks.com
Friday, 22 November 2024
09:00	60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV	accesswire.com
Monday, 11 November 2024
07:00	Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial	globenewswire.com
Monday, 4 November 2024
07:08	Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia	globenewswire.com
Friday, 18 October 2024
09:06	Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson	globenewswire.com
Wednesday, 9 October 2024
07:00	FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer	globenewswire.com
Monday, 16 September 2024
07:00	Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health	globenewswire.com
Thursday, 29 August 2024
08:15	Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies	globenewswire.com
Friday, 9 August 2024
09:00	OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV	accesswire.com
Thursday, 8 August 2024
19:01	Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds	globenewswire.com
Monday, 29 July 2024
07:00	Can-Fite Provides Namodenoson Patent Update	globenewswire.com
Wednesday, 17 July 2024
07:00	Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8	globenewswire.com
Thursday, 11 July 2024
07:00	Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer	globenewswire.com
Monday, 24 June 2024
07:00	Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver	businesswire.com
Monday, 10 June 2024
07:00	Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study	businesswire.com
Wednesday, 5 June 2024
07:00	Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study	businesswire.com
Wednesday, 29 May 2024
07:00	Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases	businesswire.com
Monday, 27 May 2024
07:00	Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024	businesswire.com
Thursday, 23 May 2024
07:00	Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on June 6	businesswire.com
Monday, 13 May 2024
07:00	Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study	businesswire.com
Friday, 10 May 2024
09:00	Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV	accesswire.com
Monday, 6 May 2024
07:00	Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602	businesswire.com
Thursday, 25 April 2024
07:00	Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal	businesswire.com
Monday, 15 April 2024
07:00	Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH	businesswire.com
Wednesday, 3 April 2024
07:00	Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients	businesswire.com
Monday, 1 April 2024
07:00	Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV	Newsfile Corp
Wednesday, 22 November 2023
09:01	Can-Fite (CANF) Up on Liver Cancer Study Update of Namodenoson	Zacks Investment Research
Tuesday, 21 November 2023
11:01	3 Top Penny Stocks To Watch Before Next Week	PennyStocks
Friday, 27 October 2023
07:31	New Strong Buy Stocks for October 27th	Zacks Investment Research

Frequently Asked Questions (FAQ)

What's the price of Can-Fite BioPharma Ltd. stock today?

One share of Can-Fite BioPharma Ltd. stock can currently be purchased for approximately $0.65.
When is Can-Fite BioPharma Ltd.'s next earnings date?

Can-Fite BioPharma Ltd. is estimated to report earnings on Thursday, 28 Aug 2025.
Does Can-Fite BioPharma Ltd. pay dividends?

No, Can-Fite BioPharma Ltd. does not pay dividends.
How much money does Can-Fite BioPharma Ltd. make?

Can-Fite BioPharma Ltd. has a market capitalization of 9.08M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 8.27% to 743K US dollars. Can-Fite BioPharma Ltd. made a loss 7.63M US dollars in net income (profit) last year or -$0.27 on an earnings per share basis.
What is Can-Fite BioPharma Ltd.'s stock symbol?

Can-Fite BioPharma Ltd. is traded on the AMEX under the ticker symbol "CANF".
What is Can-Fite BioPharma Ltd.'s primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Can-Fite BioPharma Ltd.?

Shares of Can-Fite BioPharma Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Can-Fite BioPharma Ltd.'s key executives?
Can-Fite BioPharma Ltd.'s management team includes the following people:
- Dr. Pnina Fishman Ph.D. Scientific Founder, Chief Executive Officer & Director(age: 77, pay: $598,000)
- Mr. Motti Farbstein Chief Operating & Financial Officer(age: 61, pay: $415,000)
- Dr. Sari Fishman Ph.D. Vice President of Bus. Devel.(age: 53, pay: $286,000)
Is Can-Fite BioPharma Ltd. founder-led company?

Yes, Can-Fite BioPharma Ltd. is a company led by its founder Dr. Pnina Fishman Ph.D..
How many employees does Can-Fite BioPharma Ltd. have?

As Jul 2024, Can-Fite BioPharma Ltd. employs 8 workers.
When Can-Fite BioPharma Ltd. went public?

Can-Fite BioPharma Ltd. is publicly traded company for more then 12 years since IPO on 6 Nov 2012.
What is Can-Fite BioPharma Ltd.'s official website?

The official website for Can-Fite BioPharma Ltd. is canfite.com.
How can i contact Can-Fite BioPharma Ltd.?

Can-Fite BioPharma Ltd. can be reached via phone at +972 3 924 1114.

Can-Fite BioPharma Ltd.

canfite.com

Exchange:

AMEX

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

+972 3 924 1114

10 Bareket Street
Petah Tikva, 4951778

CIK: 0001536196
ISIN: US13471N3008
CUSIP: 13471N201